引言胆道疾病是主要的急性普通外科手术负担。腹腔镜胆囊切除术是手术的金标准,尽管它在疫情爆发期间已停产。有效的管理允许决定性的治疗,症状缓解,更少的住院和并发症。在整个最初的COVID-19情况下,患者的外科手术被推迟。采用保守或非手术治疗需要侵入性服务,这可能会导致复发和胆胰腺问题增加。目的检查COVID-19对胆结石患者预后和住院的影响,胆道,和胰腺疾病。方法回顾性分析纳入到本单位就诊的具有以下ICD-10编码的患者:胆石症(K80),胆囊炎(K81),急性胰腺炎(K85)。我们比较了第一波COVID-19大流行的间隔,从2020年3月到8月,在大流行之前,称为Pre-COVID-19。应用排除标准后,共有868名患者参加了试验,最初招募了大约1400名使用这些代码的人。编码不准确的患者,癌症,或非结石疾病被排除(例如,酒精性胰腺炎)。人口统计信息,录取细节,调查,手术治疗,操作细节,并记录患者的术后并发症。手术管理的变化,患者代表,术后并发症是关键结局.结果COVID组的重复表现有统计学意义(p<0.05)。很可能是由于最终治疗的失败。另一个结果是演讲的分布是可比的,急性胆囊炎和胆石性胰腺炎患者的确定性治疗率较低(p<0.05)。结论在COVID期间,除癌症手术外,所有手术都停止了。未知的原因导致了与胆囊有关的几种后果,胆道,和胰腺。胆囊炎患者,胆结石性胰腺炎,和胰腺炎症经历了较低的概率的治疗。住院和自我陈述的增加表明,确定性治疗,旨在限制COVID-19的暴露,实际上增加了患者的风险。尽管有这种风险,我们队列中没有COVID-19病例。大流行对急性胰腺炎及其护理的长期后果的评估将需要大规模,多中心调查。
Introduction Biliary diseases are a major acute general surgical burden. Laparoscopic cholecystectomy is the gold standard surgical procedure, although it was discontinued during an outbreak. Effective management permits decisive therapy, symptom alleviation, and fewer hospitalizations and complications. Throughout the initial COVID-19 situation, surgical procedures for patients were delayed. Invasive services were required to employ conservative or non-operative therapy, which could lead to increased recurring presentations and biliary-pancreatic problems. Aim Examining the impact of COVID-19 on the outcomes and hospitalizations of patients suffering from gallstone, biliary tract, and pancreatic diseases. Methods The retrospective analysis included patients with the following ICD-10 codes who presented to our unit: cholelithiasis (K80), cholecystitis (K81), and acute pancreatitis (K85). We compared the interval of the first COVID-19 pandemic wave, from March to August 2020, with the period before the pandemic, referred to as Pre-COVID-19. After applying exclusion criteria, a total of 868 patients were enrolled in the trial, having initially recruited around 1,400 individuals using these codes. Patients with inaccurate coding, cancer, or non-stone disease were excluded (e.g., alcoholic pancreatitis). The demographic information, admission details, investigations, surgical therapy, operating specifics, and postoperative complications of the patients were noted. Changes in surgical management, patient representation, and postoperative complications were the key outcomes. Results A statistically significant (p<0.05) rise was seen in repeat presentations in the COVID group, most likely due to the failure of definitive treatment. The other outcome is the distribution of presentations was comparable, patients with acute cholecystitis and gallstone pancreatitis showed statistically significant (p<0.05) lower rates of definitive therapy. Conclusion During the COVID period, all surgeries except those for cancer were halted. Unknown causes led to several consequences related to the gallbladder, biliary tract, and pancreas. Patients with cholecystitis, gallstone pancreatitis, and pancreatic inflammation experienced a lower probability of treatment. The increase in hospitalizations and self-presentations indicated that definitive therapy, designed to restrict COVID-19 exposure, actually increased patient risk. Despite this risk, we had no COVID-19 instances in our cohort. The evaluation of the long-term consequences of the pandemic on acute pancreatitis and its care will require a large-scale, multicenter investigation.